<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05017649</url>
  </required_header>
  <id_info>
    <org_study_id>2021-07</org_study_id>
    <secondary_id>ID-RCB</secondary_id>
    <nct_id>NCT05017649</nct_id>
  </id_info>
  <brief_title>Role of A2A Receptor in Hypercholesterolemic Patients</brief_title>
  <acronym>RASCAS</acronym>
  <official_title>Characterization of Adenosine A2A Receptor Expression and Fubnction in Hypercholesterolemic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypercholesterolemia promotes chronic inflammation, endothelial dysfunction, atherosclerosis&#xD;
      and is a major risk factor for cardiovascular disease (CVD). Treatment with lipid-lowering&#xD;
      drugs (statins, ezetimibe, PCSK9 inhibitors or LDL-apheresis) reduces the risk of major&#xD;
      cardiovascular events in proportion to the absolute reduction of LDL-cholesterol (LDL-C).&#xD;
      Nevertheless, a better understanding of the effects of hypercholesterolemia on the&#xD;
      cardiovascular and immune systems could help identify all the mechanisms responsible for the&#xD;
      excess risk of CVD in hypercholesterolemic patients and develop better prevention and&#xD;
      treatment strategies.&#xD;
&#xD;
      Adenosine via A2A receptors (A2AR) plays a crucial role in the regulation of the&#xD;
      cardiovascular and immune systems.&#xD;
&#xD;
      In this project, the investigators wish :&#xD;
&#xD;
        -  To study whether the expression and function of A2AR in PBMCs are altered in human&#xD;
           hypercholesterolemia, using as a study model a larger cohort of patients with&#xD;
           hypercholesterolemia of increasing level and severity: polygenic form, heterozygous&#xD;
           genetic form and homozygous genetic form in comparison with healthy subjects with normal&#xD;
           cholesterol levels.&#xD;
&#xD;
        -  To study whether A2AR expression and function in PBMCs are associated with blood levels&#xD;
           of LDL-C and homocysteine and with the inflammatory status of patients.&#xD;
&#xD;
        -  To assess whether the cholesterol-lowering therapies currently used to reduce LDL-C&#xD;
           levels and thus the risk of CVD in hypercholesterolemic patients have an impact on&#xD;
           possible alterations of A2AR expression and function in PBMCs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 19, 2021</start_date>
  <completion_date type="Anticipated">June 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantification of A2AR expression in PBMCs</measure>
    <time_frame>Baseline</time_frame>
    <description>Comparison between hypercholesterolemic patients and healthy volunteers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantification of A2AR expression in PBMCs</measure>
    <time_frame>3 months after initiation of treatment</time_frame>
    <description>Comparison between hypercholesterolemic patients and healthy volunteers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantification of A2AR function in PBMC</measure>
    <time_frame>3 months after initiation of treatment</time_frame>
    <description>Comparison between hypercholesterolemic patients and healthy volunteers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantification of A2AR function in PBMC</measure>
    <time_frame>Baseline</time_frame>
    <description>Comparison between hypercholesterolemic patients and healthy volunteers</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>volunteers showing no hypercholesterolemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with untreated hypercholesterolemia at the time of inclusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients presenting hypercholesterolemia with no treatment at the time of inclusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with treated hypercholesterolemia at the time of inclusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients presenting hypercholesterolemia and treated at the time of inclusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Blood sampling.</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Patients with treated hypercholesterolemia at the time of inclusion</arm_group_label>
    <arm_group_label>Patients with untreated hypercholesterolemia at the time of inclusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects aged 18-80 years&#xD;
&#xD;
          -  For the group of hypercholesterolemic patients :&#xD;
&#xD;
               -  LDL-cholesterol level &gt;1.9 g/L with or without treatment to make the diagnosis of&#xD;
                  hypercholesterolemia (laboratory test less than 12 months old at inclusion)&#xD;
&#xD;
          -  For the healthy group :&#xD;
&#xD;
             ● No cholesterol-modifying therapy.&#xD;
&#xD;
          -  Subject not having hypercholesterolemia (biological assessment less than 12 months old&#xD;
             at inclusion with LDL-cholesterol level &lt; 1.9 g/L) and not taking cholesterol-lowering&#xD;
             treatment.&#xD;
&#xD;
          -  Subjects who are affiliated or beneficiaries of a social security plan&#xD;
&#xD;
          -  Subject agreeing to participate in the study and having signed an informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Protected person, as defined by articles L1121-5, L1121-6 and L1121-8 of the Public&#xD;
             Health Code: pregnant or breastfeeding woman, person deprived of liberty by judicial&#xD;
             decision, adult person unable to give consent.&#xD;
&#xD;
          -  Person who does not understand the French language&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François CREMIEUX</last_name>
    <role>Study Director</role>
    <affiliation>AP-HM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>René Valero</last_name>
    <phone>0491387577</phone>
    <phone_ext>33</phone_ext>
    <email>rene.valero@ap-hm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>René Valéro</last_name>
    <phone>0491387577</phone>
    <phone_ext>33</phone_ext>
    <email>rene.valero@ap-hm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service Endocrinologie</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>René VALERO, MD</last_name>
      <email>rene.valero@ap-hm.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 17, 2021</study_first_submitted>
  <study_first_submitted_qc>August 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypercholesterolemia</keyword>
  <keyword>adenosine receptor</keyword>
  <keyword>PBMC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

